Thoracic oncology & lung cancer represent one of the most intensively researched areas in respiratory medicine, driven by high mortality rates and complex diagnostic challenges. Advances in molecular profiling and immunotherapy have enabled oncologists and pulmonologists to personalize treatment strategies based on tumor genotypes. The use of targeted therapies and checkpoint inhibitors has significantly improved survival outcomes, particularly in advanced non-small cell lung cancer. Emerging tools such as liquid biopsies and next-generation sequencing are facilitating earlier detection and better monitoring of disease recurrence. Multidisciplinary tumor boards now play a crucial role in managing comorbidities and ensuring evidence-based treatment decisions. Additionally, growing emphasis is being placed on addressing global disparities in care access, highlighting the need for international collaboration to standardize lung cancer screening and enhance equity in therapeutic advancements.
Title : Changing population immunity to COVID-19 in the context of infection, vaccination and emerging SARS-CoV-2 variants
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Non-canonical IRF3 functions in limiting pulmonary inflammation
Saurabh Chattopadhyay, University of Kentucky, United States
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : The representational challenge for designing and managing intelligent and ethical 5P medicine pulmonary, respiratory and lung health care systems
Habil Bernd Blobel, University of Regensburg, Germany
Title : From Chronic Obstructive Pulmonary Disease (COPD) to Non-Small Cell Lung Cancer (NSCLC): T helper cell epigenetic modifications and cancer risk
Koustav Sarkar, SRM Institute of Science and Technology, India
Title : Bacterial profile of community acquired pneumonia in a public health institute
Sayan Bhattacharyya, AIIH&PH, India